Literature DB >> 2981868

Apolipoprotein C-II mRNA levels in primate liver. Induction by estrogen in the human hepatocarcinoma cell line, HepG2.

T K Archer, S P Tam, K V Deugau, R G Deeley.   

Abstract

We have demonstrated that physiological concentrations of 17 beta-estradiol increase nuclear estrogen-specific binding sites in the human hepatoma cell line HepG2 7- to 10-fold and the rate of accumulation of secreted apolipoprotein C-II (apo-C-II), 2.5-fold (Tam, S-P., Archer, T. K., and Deeley, R. G. (1985) J. Biol. Chem. 260, 1670-1675). Apo-C-II is the major activator of lipoprotein lipase, an enzyme which plays a key role in lipoprotein catabolism. In order to define more precisely the mechanism by which estrogen influences apo-C-II production, we have synthesized a triacontanucleotide DNA probe that is complementary to apo-C-II mRNA. We have used the probe both in Northern hybridization experiments and in DNA excess titrations to quantify apo-C-II mRNA in hormonally treated HepG2 cells and various primate tissues. These studies revealed that: 1) the concentration of apo-C-II mRNA in HepG2 cells is comparable with that present in human liver; 2) treatment of the cells with low levels of estrogen results in a doubling of the apo-C-II mRNA concentration; 3) the apo-C-II mRNA concentration in monkey liver is 60- to 70-fold greater than in the intestine and 2.5-fold higher than in human liver.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2981868

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  19 in total

1.  Regulation of P-glycoprotein gene expression in hepatocyte cultures and liver cell lines by a trans-acting transcriptional repressor.

Authors:  T W Gant; J A Silverman; S S Thorgeirsson
Journal:  Nucleic Acids Res       Date:  1992-06-11       Impact factor: 16.971

2.  Sequence-specific DNA binding by glucocorticoid receptor "zinc finger peptides".

Authors:  T K Archer; G L Hager; J G Omichinski
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

3.  Characterization of the rat mdr2 promoter and its regulation by the transcription factor Sp1.

Authors:  P C Brown; J A Silverman
Journal:  Nucleic Acids Res       Date:  1996-08-15       Impact factor: 16.971

4.  Further cellular investigation of the human hepatoblastoma-derived cell line HepG2: morphology and immunocytochemical studies of hepatic-secreted proteins.

Authors:  M E Bouma; E Rogier; N Verthier; C Labarre; G Feldmann
Journal:  In Vitro Cell Dev Biol       Date:  1989-03

5.  Biphasic effects of estrogen on apolipoprotein synthesis in human hepatoma cells: mechanism of antagonism by testosterone.

Authors:  S P Tam; T K Archer; R G Deeley
Journal:  Proc Natl Acad Sci U S A       Date:  1986-05       Impact factor: 11.205

6.  Transcription factor access is mediated by accurately positioned nucleosomes on the mouse mammary tumor virus promoter.

Authors:  T K Archer; M G Cordingley; R G Wolford; G L Hager
Journal:  Mol Cell Biol       Date:  1991-02       Impact factor: 4.272

7.  Cloning and regulation of the rat mdr2 gene.

Authors:  P C Brown; S S Thorgeirsson; J A Silverman
Journal:  Nucleic Acids Res       Date:  1993-08-11       Impact factor: 16.971

8.  Developmental regulation of specific protein interactions with an enhancerlike binding site far upstream from the avian very-low-density apolipoprotein II gene.

Authors:  P A Hoodless; R N Roy; A K Ryan; R J Haché; M Z Vasa; R G Deeley
Journal:  Mol Cell Biol       Date:  1990-01       Impact factor: 4.272

9.  Nucleoprotein structure influences the response of the mouse mammary tumor virus promoter to activation of the cyclic AMP signalling pathway.

Authors:  W D Pennie; G L Hager; C L Smith
Journal:  Mol Cell Biol       Date:  1995-04       Impact factor: 4.272

10.  Cisplatin inhibits chromatin remodeling, transcription factor binding, and transcription from the mouse mammary tumor virus promoter in vivo.

Authors:  J S Mymryk; E Zaniewski; T K Archer
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-14       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.